Oral insulin therapy

Details Oral insulin therapy Oral insulin therapy

2003-01-07

2008-09-30

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07429564

ABSTRACT:
Pharmaceutical dosage forms for oral administration to a patient for the treatment of diabetes, comprising insulin and a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and that result in a lower incidence of vascular diseases associated with the repeated administration of insulin are disclosed. Also disclosed is a method of attenuating the undesirable incidence of diseases associated with chronic dosing of insulin is provided whereby the oral administration to a patient of insulin along with a suitable delivery agent that facilitates the absorption of insulin from the gastrointestinal tract of the patient in a therapeutically effective amount, for treatment of diabetes.

REFERENCES:
patent: 4849227 (1989-07-01), Cho
patent: 5698515 (1997-12-01), Plate et al.
patent: 6399090 (2002-06-01), Shehadeh
patent: 6540982 (2003-04-01), Adjei et al.
patent: 6610649 (2003-08-01), Wahren et al.
patent: 7060675 (2006-06-01), Ekwuribe et al.
patent: 7084114 (2006-08-01), Ekwuribe et al.
patent: 7115663 (2006-10-01), Moye-Sherman et al.
patent: 7118762 (2006-10-01), Byrd
patent: 7137951 (2006-11-01), Pilarski
patent: 2001/0056063 (2001-12-01), Weiner et al.
patent: 2002/0003179 (2002-01-01), Verhoff et al.
patent: 2002/0147135 (2002-10-01), Schnell
patent: WO 02/02509 (2002-01-01), None
Miller J. L., “Bedtime Insulin Added to Daytime Sulfonylureas Improves Glycemic Control in Uncontrolled Type II Diabetes”, Clinical Pharmacology and Theraputics, vol. 53, No. 3., pp. 380-384, Mar. 1993.
Mesiha Mounir S., “Oral Absorption of Insulin Encapsulated in Artificial Chyles of Bile Salt, Palmitic Acid and α-Tocopherol Dispersions”, International Journal of Pharmaceutics, vol. 249, No. 1-2, pp. 1-5, 2002.
Hosny Ehab A., “Oral Delivery of Insulin from Enteric-coated Capsules Containing Sodium Salicylate: Effect on Relative Hypoglycemia of Diabetic Beagle Dogs”, International Journal of Pharmaceutics, vol. 237, No. 1-2, pp. 71-76, 2002.
Yki-Jarvinen H., “Comparison of Bedtime Insulin Regimens in Patients with Type II Diabetes Mellitus. A randomized, controlled trial.”, Annals of Internal Medicine, vol. 130, No. 5, pp. 389-396, Mar. 2, 1999.
Clement Stephen, “Oral Insulin Product Hexyl-Insulin Monoconjugate 2 (HIM2) in Type 1 Diabetes Mellitus: The Glucose Stabilization Effects of HIM2”, Diabetes Technology & Therapeutics, V. 4, No. 4, pp. 459-466, Aug. 2002.

Affiliated with

Also associated with

Rating

Oral insulin therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral insulin therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral insulin therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3970338